

WEST

Freeform Search

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

13 same 14

Display:

10

Documents in Display Format:

-

Starting with Number

20

Generate: Hit List Hit Count Side by Side Image

Search History

DATE: Thursday, September 04, 2003 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ</i>			
<u>L5</u>	13 same 14	153	<u>L5</u>
<u>L4</u>	pharm\$5 or therap\$5	384078	<u>L4</u>
<u>L3</u>	fenofibrate	814	<u>L3</u>
<i>DB=PGPB; PLUR=YES; OP=ADJ</i>			
<u>L2</u>	20020086070	1	<u>L2</u>
<u>L1</u>	20020086062	1	<u>L1</u>

END OF SEARCH HISTORY

Main compound in claim 1 Searched by library.

WEST

End of Result Set

 [Generate Collection](#) [Print](#)

L5: Entry 153 of 153

File: DWPI

Aug 30, 1989

DERWENT-ACC-NO: 1989-250607

DERWENT-WEEK: 200161

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Capsules contg. co:micronised fenofibrate and solid surfactant - allowing single oral daily dose, useful as anti-hyperlipaemic and anti-hypercholesterolaemic agent

INVENTOR: CURTET, B; REGINAULT, P; TEILLAUD, E

PATENT-ASSIGNEE:

ASSIGNEE

FOURNIER IND & SANTE

FOURNIER INNOVATION

*Ref
this.*

CODE

FOURN

FOURN

PRIORITY-DATA: 1988FR-0002359 (February 26, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 330532 A	August 30, 1989	F	008	
US 4895726 C1	August 28, 2001		000	A61K009/64
FR 2627696 A	September 1, 1989		000	
AU 8929828 A	August 31, 1989		000	
JP 01254624 A	October 11, 1989		000	
US 4895726 A	January 23, 1990		005	
EP 330532 B1	December 16, 1992	F	011	A61K009/16
DE 68903846 E	January 28, 1993		000	A61K009/16
CA 1322529 C	September 28, 1993		000	A61K031/215
ES 2054040 T3	August 1, 1994		000	A61K009/16
JP 95014876 B2	February 22, 1995		005	A61K031/22

DESIGNATED-STATES: AT BE CH DE ES FR GB GR IT LI LU NL SE AT BE CH DE ES FR GB GR IT LI LU NL SE

CITED-DOCUMENTS:EP 179583; EP 239541 ; EP 256933 ; WO 8201649

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	descriptor
EP 330532A	January 30, 1989	1989EP-0400247	
US 4895726C1	January 19, 1989	1989US-0299073	
FR 2627696A	February 26, 1988	1988FR-0002359	
JP 01254624A	February 21, 1989	1989JP-0041471	
US 4895726A	January 19, 1989	1989US-0299073	
EP 330532B1	January 30, 1989	1989EP-0400247	
DE 68903846E	January 30, 1989	1989DE-0603846	
DE 68903846E	January 30, 1989	1989EP-0400247	
DE 68903846E		EP 330532	Based on
CA 1322529C	January 31, 1989	1989CA-0589673	
ES 2054040T3	January 30, 1989	1989EP-0400247	
ES 2054040T3		EP 330532	Based on
JP 95014876B2	February 21, 1989	1989JP-0041471	
JP 95014876B2		JP 1254624	Based on

INT-CL (IPC): A61K 9/16; A61K 9/48; A61K 9/54; A61K 9/64; A61K 31/21; A61K 31/215; A61K 31/22; A61K 31/235; A61K 45/08; A61K 47/00; C07C 69/73

ABSTRACTED-PUB-NO: EP 330532A

BASIC-ABSTRACT:

Capsules contg. in solid, co-micronised form, fenofibrate (I) and a solid surface active agent (II), are new.

The wt. ratio of (II)/(I) is generally 0.75-10.5/100. The unit dose of (I) is 200 mg, and the pref. surfactant (II) is sodium lauryl sulphate. The particle size of (I) and (II) is generally less than 15 microns preferably below or equal to 5 microns. Other components that may be present include dispersing agents, fillers and flow agents.

USE/ADVANTAGE - (I) is a known anti-hyperlipidemic and anti-cholesterolemic agent. The novel formulations enable treatment to be given as a single oral daily dose.

ABSTRACTED-PUB-NO:

EP 330532B

EQUIVALENT-ABSTRACTS:

A therapeutic composition, which is useful especially in the oral treatment of hyperlipidaemia and hypercholesterolaemia, said composition containing fenofibrate and a solid surfactant which have been co-micronised.

US 4895726A

Therapeutic compsn. comprises gelatin capsules contg. a co-micronised mixt. of (i) particles of fenofibrate and (ii) a solid surfactant, and particle size less than 15 microns.

Pref. wt. ratio (ii):(i) is 0.75-10.5/100. Amt. of (i) comprises 200 mg per therapeutic unit. Cpd. (b) is 0.5-7 wt.% of sodium lauryl-sulphate w.r.t. total. Opt. dispersants, fillers and flow enhancers are included in the compsn.

USE - For orally treating hyperlipidaemia and hypercholesterolaemia, having improved bioavailability. (5pp)u

CHOSEN-DRAWING: Dwg.0/1 Dwg.0/1

TITLE-TERMS: CAPSULE CONTAIN CO MICRONISED SOLID SURFACTANT ALLOW SINGLE ORAL DAILY DOSE USEFUL ANTI HYPERLIPAEAMIA ANTI HYPERCHOLESTEROLAEMIC AGENT